Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium

Sneha Sundaram, Shyamal K Roy, Balamurali K. Ambati, Uday B. Kompella

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The objective of this study was to determine whether surface-modified nanoparticles enhance permeability across nasal mucosa, while retaining the effectiveness of the payload. The uptake and permeability of polystyrene nanoparticles (PS-NPs; Fluo-Spheres) was evaluated across the various regions of the bovine nasal epithelia following conjugation with deslorelin and transferrin. Uptake and transport of PS-NPs, deslorelin-PS-NPs, and transferrin-PS-NPs exhibited regional differences in the order: inferior turbinate posterior (ITP) > medium turbinate posterior (MTP) > medium turbinate anterior (MTA). Uptake and transport also exhibited directionality and temperature dependence in these tissues. Further, uptake as well as transport of functionalized nanoparticles could be inhibited by excess free functionalizing ligand. Confocal microscopy indicated the presence of functionalized nanoparticles in respiratory epithelial cells, as well as other cell types of the nasal tissue. We chose the ITP region for further studies with deslorelin or transferrin-conjugated poly-L-lactide-co-glycolide nanoparticles (PLGA-NPs) encapsulating an anti-VEGF intraceptor (Flt23k) plasmid. Transport of the nanoparticles, as well as the plasmid from the nanoparticles, exhibited the following order: transferrin-PLGA-NPs > deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. The ability of the nanoparticles transported across the nasal tissue to retain the effectiveness of the Flt23k plasmid was evaluated by measuring transfection efficiency (percentage of cells expressing GFP) and VEGF inhibition in LNCaP and PC-3 prostate cancer cells. Transfection efficiencies and VEGF inhibition in LNCaP and PC-3 cells exhibited the following trend: transferrin-PLGA-NPs ≥ deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. Further, functionalized nanoparticles exhibited transfection efficiencies and VEGF inhibition significantly superior compared with the routinely used transfecting agent, lipofectamine. Formulating plasmids into nanoparticulate delivery systems enhances the transnasal delivery and gene therapy at remote target cancer cells, which can be further enhanced by nanoparticle functionalization with deslorelin or transferrin.

Original languageEnglish (US)
Pages (from-to)3752-3765
Number of pages14
JournalFASEB Journal
Volume23
Issue number11
DOIs
StatePublished - Nov 5 2009

Fingerprint

Respiratory Mucosa
Nasal Mucosa
Nanoparticles
Genes
Transferrin
Turbinates
Plasmids
Vascular Endothelial Growth Factor A
Transfection
Cells
Tissue
Nose
Permeability
Polyglactin 910
Gene therapy
Confocal microscopy
Polystyrenes
polylactic acid-polyglycolic acid copolymer
Confocal Microscopy
Genetic Therapy

Keywords

  • Anti-VEGF intraceptor
  • Deslorelin
  • Gene therapy
  • Poly-L-lactide-co-glycolide
  • Prostate cancer
  • Transferrin

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. / Sundaram, Sneha; Roy, Shyamal K; Ambati, Balamurali K.; Kompella, Uday B.

In: FASEB Journal, Vol. 23, No. 11, 05.11.2009, p. 3752-3765.

Research output: Contribution to journalArticle

Sundaram, Sneha ; Roy, Shyamal K ; Ambati, Balamurali K. ; Kompella, Uday B. / Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. In: FASEB Journal. 2009 ; Vol. 23, No. 11. pp. 3752-3765.
@article{462d7d6858674469b6d1b9940ec558e6,
title = "Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium",
abstract = "The objective of this study was to determine whether surface-modified nanoparticles enhance permeability across nasal mucosa, while retaining the effectiveness of the payload. The uptake and permeability of polystyrene nanoparticles (PS-NPs; Fluo-Spheres) was evaluated across the various regions of the bovine nasal epithelia following conjugation with deslorelin and transferrin. Uptake and transport of PS-NPs, deslorelin-PS-NPs, and transferrin-PS-NPs exhibited regional differences in the order: inferior turbinate posterior (ITP) > medium turbinate posterior (MTP) > medium turbinate anterior (MTA). Uptake and transport also exhibited directionality and temperature dependence in these tissues. Further, uptake as well as transport of functionalized nanoparticles could be inhibited by excess free functionalizing ligand. Confocal microscopy indicated the presence of functionalized nanoparticles in respiratory epithelial cells, as well as other cell types of the nasal tissue. We chose the ITP region for further studies with deslorelin or transferrin-conjugated poly-L-lactide-co-glycolide nanoparticles (PLGA-NPs) encapsulating an anti-VEGF intraceptor (Flt23k) plasmid. Transport of the nanoparticles, as well as the plasmid from the nanoparticles, exhibited the following order: transferrin-PLGA-NPs > deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. The ability of the nanoparticles transported across the nasal tissue to retain the effectiveness of the Flt23k plasmid was evaluated by measuring transfection efficiency (percentage of cells expressing GFP) and VEGF inhibition in LNCaP and PC-3 prostate cancer cells. Transfection efficiencies and VEGF inhibition in LNCaP and PC-3 cells exhibited the following trend: transferrin-PLGA-NPs ≥ deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. Further, functionalized nanoparticles exhibited transfection efficiencies and VEGF inhibition significantly superior compared with the routinely used transfecting agent, lipofectamine. Formulating plasmids into nanoparticulate delivery systems enhances the transnasal delivery and gene therapy at remote target cancer cells, which can be further enhanced by nanoparticle functionalization with deslorelin or transferrin.",
keywords = "Anti-VEGF intraceptor, Deslorelin, Gene therapy, Poly-L-lactide-co-glycolide, Prostate cancer, Transferrin",
author = "Sneha Sundaram and Roy, {Shyamal K} and Ambati, {Balamurali K.} and Kompella, {Uday B.}",
year = "2009",
month = "11",
day = "5",
doi = "10.1096/fj.09-129825",
language = "English (US)",
volume = "23",
pages = "3752--3765",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "11",

}

TY - JOUR

T1 - Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium

AU - Sundaram, Sneha

AU - Roy, Shyamal K

AU - Ambati, Balamurali K.

AU - Kompella, Uday B.

PY - 2009/11/5

Y1 - 2009/11/5

N2 - The objective of this study was to determine whether surface-modified nanoparticles enhance permeability across nasal mucosa, while retaining the effectiveness of the payload. The uptake and permeability of polystyrene nanoparticles (PS-NPs; Fluo-Spheres) was evaluated across the various regions of the bovine nasal epithelia following conjugation with deslorelin and transferrin. Uptake and transport of PS-NPs, deslorelin-PS-NPs, and transferrin-PS-NPs exhibited regional differences in the order: inferior turbinate posterior (ITP) > medium turbinate posterior (MTP) > medium turbinate anterior (MTA). Uptake and transport also exhibited directionality and temperature dependence in these tissues. Further, uptake as well as transport of functionalized nanoparticles could be inhibited by excess free functionalizing ligand. Confocal microscopy indicated the presence of functionalized nanoparticles in respiratory epithelial cells, as well as other cell types of the nasal tissue. We chose the ITP region for further studies with deslorelin or transferrin-conjugated poly-L-lactide-co-glycolide nanoparticles (PLGA-NPs) encapsulating an anti-VEGF intraceptor (Flt23k) plasmid. Transport of the nanoparticles, as well as the plasmid from the nanoparticles, exhibited the following order: transferrin-PLGA-NPs > deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. The ability of the nanoparticles transported across the nasal tissue to retain the effectiveness of the Flt23k plasmid was evaluated by measuring transfection efficiency (percentage of cells expressing GFP) and VEGF inhibition in LNCaP and PC-3 prostate cancer cells. Transfection efficiencies and VEGF inhibition in LNCaP and PC-3 cells exhibited the following trend: transferrin-PLGA-NPs ≥ deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. Further, functionalized nanoparticles exhibited transfection efficiencies and VEGF inhibition significantly superior compared with the routinely used transfecting agent, lipofectamine. Formulating plasmids into nanoparticulate delivery systems enhances the transnasal delivery and gene therapy at remote target cancer cells, which can be further enhanced by nanoparticle functionalization with deslorelin or transferrin.

AB - The objective of this study was to determine whether surface-modified nanoparticles enhance permeability across nasal mucosa, while retaining the effectiveness of the payload. The uptake and permeability of polystyrene nanoparticles (PS-NPs; Fluo-Spheres) was evaluated across the various regions of the bovine nasal epithelia following conjugation with deslorelin and transferrin. Uptake and transport of PS-NPs, deslorelin-PS-NPs, and transferrin-PS-NPs exhibited regional differences in the order: inferior turbinate posterior (ITP) > medium turbinate posterior (MTP) > medium turbinate anterior (MTA). Uptake and transport also exhibited directionality and temperature dependence in these tissues. Further, uptake as well as transport of functionalized nanoparticles could be inhibited by excess free functionalizing ligand. Confocal microscopy indicated the presence of functionalized nanoparticles in respiratory epithelial cells, as well as other cell types of the nasal tissue. We chose the ITP region for further studies with deslorelin or transferrin-conjugated poly-L-lactide-co-glycolide nanoparticles (PLGA-NPs) encapsulating an anti-VEGF intraceptor (Flt23k) plasmid. Transport of the nanoparticles, as well as the plasmid from the nanoparticles, exhibited the following order: transferrin-PLGA-NPs > deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. The ability of the nanoparticles transported across the nasal tissue to retain the effectiveness of the Flt23k plasmid was evaluated by measuring transfection efficiency (percentage of cells expressing GFP) and VEGF inhibition in LNCaP and PC-3 prostate cancer cells. Transfection efficiencies and VEGF inhibition in LNCaP and PC-3 cells exhibited the following trend: transferrin-PLGA-NPs ≥ deslorelin-PLGA-NPs > PLGA-NPs ≫ plasmid. Further, functionalized nanoparticles exhibited transfection efficiencies and VEGF inhibition significantly superior compared with the routinely used transfecting agent, lipofectamine. Formulating plasmids into nanoparticulate delivery systems enhances the transnasal delivery and gene therapy at remote target cancer cells, which can be further enhanced by nanoparticle functionalization with deslorelin or transferrin.

KW - Anti-VEGF intraceptor

KW - Deslorelin

KW - Gene therapy

KW - Poly-L-lactide-co-glycolide

KW - Prostate cancer

KW - Transferrin

UR - http://www.scopus.com/inward/record.url?scp=70350544117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350544117&partnerID=8YFLogxK

U2 - 10.1096/fj.09-129825

DO - 10.1096/fj.09-129825

M3 - Article

VL - 23

SP - 3752

EP - 3765

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 11

ER -